Giles K, et al. Real-world efficacy of delayed-release dimethyl fumarate in early multiple sclerosis: interim results from ESTEEM. ECTRIMS 2018, P595.
Extra voordeel langere dosisinterval natalizumab: minder JCV-conversie
mei 2025 | Multipele Sclerose